

Haloperidol (7001): sc-66046

BACKGROUND

Haloperidol, sold under a variety of names, including Aloperidin, Brotopon and Dozic, is a butyrophenone antipsychotic drug that is used to treat delirium and acute psychotic states, such as schizophrenia. Developed in the 1950's by a Belgian company, Haloperidol functions as a strong neuroleptic that blocks dopaminergic receptors in the limbic system and the mesocortex, thereby preventing dopaminergic action in the brain (which is thought to cause the lack of motor coordination associated with many mental illnesses). Additionally, Haloperidol serves as an effective treatment for mania and can also be used to suppress agitation, to treat severe chronic pain and to relieve nausea associated with chemotherapy. While Haloperidol is over 50 times more effective than similar drugs, it has several side effects which include constipation, dry mouth, hypotension, sedation and lactation in both sexes.

REFERENCES

1. Brauer, L.H., Cramblett, M.J., Paxton, D.A. and Rose, J.E. 2001. Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. *Psychopharmacology* 159: 31-37.
2. Halim, N.D., Weickert, C.S., McClintock, B.W., Weinberger, D.R. and Lipska, B.K. 2004. Effects of chronic Haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. *Neuropsychopharmacology* 29: 1063-1069.
3. Rosow, C.E., Haspel, K.L., Smith, S.E., Grecu, L. and Bittner, E.A. 2008. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting. *Anesth. Analg.* 106: 1407-1409.
4. Fiore, M., Di Fausto, V., Iannitelli, A. and Aloe, L. 2008. Clozapine or Haloperidol in rats prenatally exposed to methylazoxymethanol, a compound inducing entorhinal-hippocampal deficits, alter brain and blood neurotrophins' concentrations. *Ann. Ist. Super. Sanita* 44: 167-177.
5. Kim, S.H., Seo, M.S., Jeon, W.J., Yu, H.S., Park, H.G., Jung, G.A., Lee, H.Y., Kang, U.G. and Kim, Y.S. 2008. Haloperidol regulates the phosphorylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex. *Int. J. Neuropsychopharmacol.* 11: 509-517.
6. Frasca, A., Fumagalli, F., Ter Horst, J., Racagni, G., Murphy, K.J. and Riva, M.A. 2008. Olanzapine, but not Haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex. *Int. J. Neuropsychopharmacol.* 11: 591-595.
7. Chen, S., Owens, G.C. and Edelman, D.B. 2008. Dopamine inhibits mitochondrial motility in hippocampal neurons. *PLoS ONE* 3: e2804.
8. Amato, D., Stasi, M.A., Borsini, F. and Nencini, P. 2008. Haloperidol both prevents and reverses quipirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia. *Psychopharmacology* 200: 157-165.
9. Leucht, C., Kitzmantel, M., Chua, L., Kane, J. and Leucht, S. 2008. Haloperidol versus chlorpromazine for schizophrenia. *Cochrane Database Syst. Rev.* 1: CD004278.

SOURCE

Haloperidol (7001) is a mouse monoclonal antibody raised against Haloperidol.

PRODUCT

Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Haloperidol (7001) is recommended for detection of Haloperidol by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.